Table 5 Effects of Dexmedetomidine on Patient and Surgeon Satisfaction
From: Perioperative Dexmedetomidine for outpatient cataract surgery: a systematic review
Study | Other Treatment Group(s) | Patient Satisfaction | Surgeon Satisfaction |
|---|---|---|---|
Abdalla [23] | saline | – | – |
Alhashemi [12] | midazolam | Increased satisfaction with sedation [median 7-point Likert-like verbal rating scale (IQR): 6 (6–7) vs 6 (5–7), P < 0.05] | No statistically significant difference (7-point Likert-like verbal rating scale) |
Altiparmak [24] | remifentanil | – | – |
Apan [11] | midazolam and saline | No statistical analyses of patient comments regarding satisfaction and effectiveness of sedation | No statistically significant difference (4-point scale) |
Ayoglu [21] | no sedation | Increased NRSa scores [data not reported, P = 0.001] | No statistically significant difference (NRS) |
Dogan [13] | midazolam-fentanyl with topical analgesia or peribulbar block | Decreased [mean patient satisfaction on 5-point scale: 3.60 and 3.65 for patients receiving midazolam, fentanyl, and topical or peribulbar block, respectively; compared to 3.15 and 2.90 for patients receiving dexmedetomidine and topical or peribulbar block, respectively; P < 0.05] | Decreased [mean surgeon satisfaction on 5-point scale: 3.75 and 3.70 for patients receiving midazolam, fentanyl, and topical or peribulbar block, respectively; compared to 3.25 and 3.25 for patients receiving dexmedetomidine and topical or peribulbar block, respectively; P < 0.05] |
Erdurmus [14] | saline | Increased score on 5-point scale [no data reported, P = 0.042] | Increased [mean surgeon satisfaction score on 5-point scale (SDb): 3.41 (0.80) vs 2.36 (1.26), P = 0.003] |
Ghodki [15] | saline | Increased [mean patient satisfaction score on 10-point scale (range): 9 (8–10) vs 7 (5–8), P = 0.0001] | Increased [surgeon satisfaction score (excellent/good): 26/4 vs 13/17, P = 0.0001] |
Kermany [10] | remifentanil | – | – |
Muttu [16] | midazolam | – | No statistically significant difference on 4-point scaled |
Na [17] | propofol-alfentanil | Increased [ISASc (SD): 50.3 (6.2) vs 42.7 (8.7), P < 0.001; and median ISAS (IQR): 50 (48–55) vs 45.0 (39–49)] | – |
Park [22] | remifentanil | No statistically significant difference in 7-point Likert-like verbal rating scale | Decreased [mean 7-point Likert-like verbal rating scale (range): 6.05 (4–7) vs 6.35 (3–7), P < 0.05] |
Virkilla [19] | placebo | – | – |
Virkilla [20] | midazolam and placebo | – | – |
Yagan [18] | ketofole | No statistically significant difference in 7-point Likert-like verbal rating scale | No statistically significant difference in 7-point Likert-like verbal rating scale |